Search results for "FrACT"

showing 10 items of 6229 documents

Tunable-frequency three-dimensional structured illumination microscopy with reduced data-acquisition

2018

The performance of a tunable three-dimensional (3D) structured illumination microscope (SIM) system and its ability to provide simultaneously super-resolution (SR) and optical-sectioning (OS) capabilities are investigated. Numerical results show that the performance of our 3D-SIM system is comparable with the one provided by a three-wave interference SIM, while requiring 40% fewer images for the reconstruction and providing frequency tunability in a cost-effective implementation. The performance of the system has been validated experimentally with images from test samples, which were also imaged with a commercial SIM based on incoherent-grid projection for comparison. Restored images from d…

0301 basic medicineMicroscopeMaterials sciencebusiness.industryStructured illumination microscopyIterative reconstructionStructured illumination01 natural sciencesAtomic and Molecular Physics and Opticslaw.invention010309 optics03 medical and health sciences030104 developmental biologyOpticsData acquisitionInterference (communication)law0103 physical sciencesbusinessProjection (set theory)Diffraction gratingOptics Express
researchProduct

Vertical root fracture resistance of simulated immature permanent teeth filled with MTA using different vehicles

2017

Background The aim of the study is to evaluate the resistance vertical root fracture (VRF) of mineral trioxide aggregate (MTA) filled-immature permanent roots by using three different vehicles. Material and Methods Forty-extracted human single-rooted mandibular premolars were selected and the root length was standardized to the length of 9 mm. For simulation of immature tooth apices, peeso reamers were introduced into the root canals and the prepared roots were assigned into three experimental groups according the used vehicle (distilled water-DW, prophylene glycol-PG, chlorhexidine-CHX) and control group (n=10). To simulate a periodontal membrane, the apical 7 mm of all roots was covered w…

0301 basic medicineMineral trioxide aggregateMaterials scienceDentistryOdontologíaOperative Dentistry and Endodontics03 medical and health sciences0302 clinical medicineVertical root fractureFlexural strengthmedicineStatistical analysisGeneral DentistryPermanent teethUniversal testing machinebusiness.industryResearch030206 dentistryTooth Apexmedicine.disease:CIENCIAS MÉDICAS [UNESCO]Ciencias de la salud030104 developmental biologyUNESCO::CIENCIAS MÉDICASFracture (geology)business
researchProduct

Incorporation of mRNA in Lamellar Lipid Matrices for Parenteral Administration

2018

Molecular pharmaceutics 15(2), 642 - 651 (2018). doi:10.1021/acs.molpharmaceut.7b01022

0301 basic medicineModels MolecularDrug CompoundingKineticsLipid BilayersPharmaceutical Science610TransfectionCell LineMyoblasts03 medical and health sciencesMiceX-Ray DiffractionCationsDrug DiscoveryScattering Small AngleAnimalsRNA Messengerddc:610Lipid bilayerLuciferasesMessenger RNALiposomeDrug CarriersChemistryAqueous two-phase systemRNATransfection030104 developmental biologyDelayed-Action PreparationsLiposomesBiophysicsMolecular Medicinelipids (amino acids peptides and proteins)Drug carrier
researchProduct

Cheek-splitting technique for marginal mandibulectomy: A novel approach

2019

When performing marginal mandibulectomy, ensuring complete tumor removal and preventing postoperative iatrogenic mandibular fracture are essential. Pathological fracture can result due to stress concentration at the site requiring acute angle resection. To perform marginal mandibulectomy without making acute angles in patients with a lesion in the molar or more posterior region, a submandibular or transbuccal approach is necessary. Compared to the submandibular approach, the transbuccal approach is considered useful as it reduces operative time and prevents injury to the facial and mental nerves. Additionally, this approach does not leave a scar in the surgical field, which is beneficial in…

0301 basic medicineMolarmedicine.medical_specialtyMandibular fracturemedicine.medical_treatmentCase Report03 medical and health sciences0302 clinical medicinestomatognathic systemMedicineGeneral Dentistrybusiness.industryGingival CarcinomaNeck dissectionCheek:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseSurgerystomatognathic diseases030104 developmental biologymedicine.anatomical_structureMandibulectomyUNESCO::CIENCIAS MÉDICASOperative timeTumor removalOral Surgerybusiness030217 neurology & neurosurgeryJournal of Clinical and Experimental Dentistry
researchProduct

The dimer-monomer equilibrium of SARS-CoV-2 main protease is affected by small molecule inhibitors

2021

AbstractThe maturation of coronavirus SARS-CoV-2, which is the etiological agent at the origin of the COVID-19 pandemic, requires a main protease Mpro to cleave the virus-encoded polyproteins. Despite a wealth of experimental information already available, there is wide disagreement about the Mpro monomer-dimer equilibrium dissociation constant. Since the functional unit of Mpro is a homodimer, the detailed knowledge of the thermodynamics of this equilibrium is a key piece of information for possible therapeutic intervention, with small molecules interfering with dimerization being potential broad-spectrum antiviral drug leads. In the present study, we exploit Small Angle X-ray Scattering (…

0301 basic medicineMolecular biologyProtein ConformationSciencemedicine.medical_treatmentDimerBiophysicsPlasma protein binding010402 general chemistryAntiviral Agents01 natural sciencesArticleDissociation (chemistry)03 medical and health scienceschemistry.chemical_compoundProtein structureX-Ray DiffractionDrug DiscoverymedicineHumansProtease InhibitorsCoronavirus 3C ProteasesVirtual screeningMultidisciplinaryProteaseSARS-CoV-2ChemistryQSARS-CoV-2 main protease Mpro enzymatic activity inhibition Small Angle X-ray Scattering small inhibitors virtual screeningRCOVID-19Computational BiologySmall moleculeComputational biology and bioinformatics0104 chemical sciencesMolecular Docking SimulationDissociation constant030104 developmental biologyBiophysicsMedicineThermodynamicsDimerizationProtein Binding
researchProduct

Role of ATP during the initiation of microvascularization: acceleration of an autocrine sensing mechanism facilitating chemotaxis by inorganic polyph…

2018

The in vitro tube formation assay with human umbilical vein endothelial cells (HUVEC) was applied to identify the extra- and intracellular sources of metabolic energy/ATP required for cell migration during the initial stage of microvascularization. Extracellularly, the physiological energy-rich polymer, inorganic polyphosphate (polyP), applied as biomimetic amorphous calcium polyP microparticles (Ca-polyP-MP), is functioning as a substrate for ATP generation most likely via the combined action of the alkaline phosphatase (ALP) and the adenylate kinase (AK). The linear Ca-polyP-MP with a size of 40 phosphate units, close to the polyP in the acidocalcisomes in the blood platelets, were found …

0301 basic medicineOligomycinAdenylate kinaseNeovascularization PhysiologicBiochemistry03 medical and health scienceschemistry.chemical_compound0302 clinical medicineAdenosine TriphosphateX-Ray DiffractionPolyphosphatesSpectroscopy Fourier Transform InfraredExtracellularHuman Umbilical Vein Endothelial CellsHumansGlycolysisMolecular BiologyTube formationATP synthasebiologyChemistryApyraseAdenylate Kinase (AK) ; Alkaline Phosphatase (ALP) ; ATP ; F0F1-ATP synthase ; inorganic polyphosphate ; microvascularization ; tube formation ; Human Umbilical Vein Endothelial Cells (HUVEC) ; nano/microparticles ; chemotaxis ; autocrine sensing.ChemotaxisCell BiologyCell biologyAutocrine Communication030104 developmental biology030220 oncology & carcinogenesisMicrovesselsbiology.proteinIntracellular
researchProduct

Phase 1b/3 study of avelumab-based combination regimens in patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL).

2017

TPS7575 Background: Approximately 50% of patients (pts) with advanced DLBCL are refractory to or relapse following first line R-CHOP therapy. Pts with R/R DLBCL have limited treatment options and a poor prognosis. This study assesses immunotherapy-based regimens containing avelumab (a fully human IgG1 anti–PD-L1 antibody) in combination with utomilumab (a novel 4-1BB agonist), azacitidine, rituximab, and/or conventional chemotherapy (CT; bendamustine) in pts with R/R DLBCL. Methods: JAVELIN DLBCL (NCT02951156) is a global, multicenter, randomized, open-label, 2-component(phase 1b followed by phase 3) study of avelumab-based combination regimens in R/R DLBCL. In phase 1b, up to 84 pts will …

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtybusiness.industryFirst lineTreatment optionsAvelumab03 medical and health sciences030104 developmental biologyOncologyRefractoryhemic and lymphatic diseasesInternal medicinemedicineRefractory Diffuse Large B-Cell LymphomaIn patientbusinessmedicine.drugJournal of Clinical Oncology
researchProduct

SAFETY AND CLINICAL ACTIVITY OF TEMSIROLIMUS IN COMBINATION WITH RITUXIMAB AND DHAP IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMP…

2017

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtybusiness.industryHematologyGeneral MedicineTemsirolimus03 medical and health sciences030104 developmental biology0302 clinical medicineOncology030220 oncology & carcinogenesisInternal medicineDHAPmedicineRefractory Diffuse Large B-Cell LymphomaIn patientRituximabbusinessmedicine.drugHematological Oncology
researchProduct

Immunotherapy is not for all comers in chemotherapy-refractory advanced gastric cancer. Better predictive biomarkers are needed

2018

0301 basic medicineOncologyChemotherapymedicine.medical_specialtybusiness.industrymedicine.medical_treatmentMEDLINEHematologyImmunotherapyAdvanced gastric cancer03 medical and health sciences030104 developmental biology0302 clinical medicineOncologyRefractory030220 oncology & carcinogenesisInternal medicineMonoclonalmedicineEsophagogastric junctionbusinessPredictive biomarkerAnnals of Oncology
researchProduct

Denosumab for bone health in prostate and breast cancer patients receiving endocrine therapy? A systematic review and a meta-analysis of randomized t…

2019

Highlights • Hormonal receptors positive breast tumor and prostate cancer are managed with endocrine therapies. • Endocrine therapies designed for breast and prostate cancer are often associated to serious adverse skeletal related events, such fractures. • Denosumab is a monoclonal anti-body binding RANKL which acts as inhibitor of osteoclasts activity, thus increasing bone mass. • Denosumab was showed to strongly prevent hormonal therapies-related skeletal issues. • Denosumab administration results safe in bone mass increase and reduction of fractures risk.

0301 basic medicineOncologyRCTs randomized clinical trialrandomized clinical trialslcsh:Diseases of the musculoskeletal systemSettore MED/06 - Oncologia MedicaOsteoporosisBMD bone mass densityReview Articleandrogen deprivation therapyADTlaw.inventionAndrogen deprivation therapyProstate cancerhazard ratio0302 clinical medicineRandomized controlled triallawHRMedicineBreastSAEsCancerProstateRANKLCIMD mean differencelcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensRCTs randomized clinical trialsDenosumabOncology030220 oncology & carcinogenesisSAEs serious adverse eventsDenosumabmean differencemedicine.drugmedicine.medical_specialtylcsh:RC254-28203 medical and health sciencesBreast cancerRANKL receptor activator of nuclear factor-kB ligandBMDInternal medicineAdverse effectADT androgen deprivation therapyRCTsbusiness.industryMDmedicine.diseaseHR hazard ratioHormonereceptor activator of nuclear factor-kB ligandDiscontinuationCI confidence interval030104 developmental biologyFractureconfidence intervalADT androgen deprivation therapy; BMD bone mass density; Breast; CI confidence interval; Cancer; Denosumab; Fracture; HR hazard ratio; Hormone; MD mean difference; Prostate; RANKL receptor activator of nuclear factor-kB ligand; RCTs randomized clinical trials; SAEs serious adverse eventsserious adverse eventsbone mass densitylcsh:RC925-935businessJournal of Bone Oncology
researchProduct